A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

November 9, 2025

Study Completion Date

November 9, 2025

Conditions

Solid Tumor

Interventions

DRUG

WX390

WX390 tablet, once a day

DRUG

Toripalimab

240 mg, Day 1, every 3 weeks

Trial Locations (1)

RECRUITING

the first affiliated hospital of Jilin university, Changchun

All Listed Sponsors

lead

Shanghai Jiatan Pharmatech Co., Ltd

INDUSTRY

NCT06117566 - A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter